TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16844267

Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli and bifidobacteria
Number of subjects: 479

Group type: COMPARATOR
Intervention: Vitamins plus minerals
Number of subjects: 479
Study: 12509548

Group type: EXPERIMENTAL
Intervention: Triple dye and alcohol treatment (n = 384)
Number of subjects: 766

Group type: COMPARATOR
Intervention: Dry care (n = 382)
Number of subjects: 766
Study: 10435201

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic olanzapine (mean daily dose at endpoint = 13.6 +/- 6.9 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic olanzapine
Number of subjects: 0
Study: 8777099

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine 20 ml via a low thoracic extradural catheter and a diclofenac suppository (100 mg) given 30 min before incision (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% plain bupivacaine 20 ml via a low thoracic extradural catheter and a diclofenac suppository (100 mg) given 30 min after incision (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups received a standard general anaesthetic and no opioid was used before or during operation.
Number of subjects: 40
Study: 1797522

Group type: EXPERIMENTAL
Intervention: Motivation programme (individual and group basis with client-centred and cognitive-behavioural therapy approaches)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Waiting list control group for 3 weeks
Number of subjects: 239
Study: 6822200

Group type: EXPERIMENTAL
Intervention: Resection of the tumour with subtotal oesophagectomy without opening the thorax.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thoraco-abdominal or transthoracic resection.
Number of subjects: 0
Study: 31526122

Group type: EXPERIMENTAL
Intervention: Higher neighborhood socioeconomic status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women and younger stroke survivors
Number of subjects: 0
Study: 29220623

Group type: EXPERIMENTAL
Intervention: AgeWISE program (n = 25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No-treatment control group (n = 24)
Number of subjects: 49
Study: 26915900

Group type: EXPERIMENTAL
Intervention: Open Door intervention
Number of subjects: 161

Group type: COMPARATOR
Intervention: Service Referral control
Number of subjects: 161
Study: 25439419

Group type: EXPERIMENTAL
Intervention: IV succinylcholine 0.3 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: IV succinylcholine 0.6 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: IV succinylcholine 1.0 mg/kg
Number of subjects: 180
Study: 23067904

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol administered before primary percutaneous coronary intervention (pPCI)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Oral metoprolol initiated post-primary percutaneous coronary intervention (pPCI)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 220
Study: 20487410

Group type: EXPERIMENTAL
Intervention: Narrative exposure therapy (NET) for 10 sessions
Number of subjects: 16
Study: 18595960

Group type: EXPERIMENTAL
Intervention: Office-based violence-prevention intervention
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (educational handout on literacy promotion)
Number of subjects: 137
Study: 16608538

Group type: EXPERIMENTAL
Intervention: Adeli suit treatment (AST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neurodevelopmental treatment (NDT)
Number of subjects: 24
Study: 14570964

Group type: EXPERIMENTAL
Intervention: Anger management
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Depression management
Number of subjects: 169

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 169
Study: 10695095

Group type: EXPERIMENTAL
Intervention: HFA-BDP (354 patients; 75%) at half their current daily dose of CFC-BDP
Number of subjects: 473

Group type: COMPARATOR
Intervention: CFC-BDP (119 patients; 25%)
Number of subjects: 473
Study: 8596569

Group type: COMPARATOR
Intervention: Alprostadil (intracavernosal injection)
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Alprostadil (minimal effective dose)
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Alprostadil (self-injection)
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Alprostadil (side effects)
Number of subjects: 1180
Study: 1849160

Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A virus vaccine (10(4.1), 10(5.2), 10(6.1), 10(7.3) TCID50)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A virus vaccine (10(7.3) TCID50)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6611963

Group type: EXPERIMENTAL
Intervention: Extra-amniotic insertion of a Foley catheter alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Extra-amniotic administration of Tylose gel
Number of subjects: 6
Study: 29249435

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60

Group type: COMPARATOR
Intervention: RIPC vs Sham
Number of subjects: 60

Group type: COMPARATOR
Intervention: RIPC vs Sham (adjusted for age and sex)
Number of subjects: 60
Study: 28697863

Group type: EXPERIMENTAL
Intervention: Intra-articular TXA (1 g intra-articularly and 50 mL intra-articular saline)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (1 g IV and 50 mL intra-articular saline)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (0 g and 50 mL intra-articular saline)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intra-articular TXA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravenous TXA
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 25158274

Group type: EXPERIMENTAL
Intervention: Retropubic sling
Number of subjects: 404

Group type: COMPARATOR
Intervention: Transobturator sling
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 404
Study: 23806675

Group type: EXPERIMENTAL
Intervention: Eat It To Beat It programme (community-based education and 'below the line' social marketing)
Number of subjects: 2804

Group type: COMPARATOR
Intervention: Control group (New England region, no intervention)
Number of subjects: 2804
Study: 21146279

Group type: EXPERIMENTAL
Intervention: Extended feedback group with voice prompts
Number of subjects: 312

Group type: COMPARATOR
Intervention: Limited feedback group with metronome and visual feedback
Number of subjects: 312
Study: 18279933

Group type: EXPERIMENTAL
Intervention: Chronic ADT (6 months or longer)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acute ADT (less than 6 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No ADT (healthy controls or prostate cancer patients not on ADT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acute ADT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chronic ADT
Number of subjects: 48
Study: 16556072

Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva) combined with carboplatin and paclitaxel chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard first-line chemotherapy
Number of subjects: 0
Study: 14601273

Group type: EXPERIMENTAL
Intervention: Needle-through-needle combined spinal-epidural (CSE)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Single-shot spinal (SSS)
Number of subjects: 89
Study: 11784964

Group type: EXPERIMENTAL
Intervention: Citicoline (1.2 g/day for 4 days after surgery)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 81
Study: 9426793

Group type: EXPERIMENTAL
Intervention: Scheduled reduced smoking
Number of subjects: 48000000
Study: 8314479

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b at a dose of 6 million units (MU) three times per week
Number of subjects: 87

Group type: COMPARATOR
Intervention: Interferon alfa‐2b at a dose of 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b at a dose of 6 MU
Number of subjects: 87
Study: 2874822

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flurazepam (15 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lormetazepam (1 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29458407

Group type: EXPERIMENTAL
Intervention: ICare Prevent (guided version)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: ICare Prevent (unguided version)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: ICare Prevent (both versions)
Number of subjects: 252
Study: 27514722

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 18
Study: 25250660

Group type: EXPERIMENTAL
Intervention: Family-based therapy (FBT)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Systemic family therapy (SyFT)
Number of subjects: 164
Study: 24064461

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study: 21175564

Group type: EXPERIMENTAL
Intervention: Methotrexate (15 mg per week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fumarates (30 mg, followed by 120 mg according to a standard progressive dosage regimen)
Number of subjects: 60
Study: 18331943

Group type: EXPERIMENTAL
Intervention: Pumice prophylaxis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonpumice group
Number of subjects: 30
Study: 16753768

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 97

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 97
Study: 14706912

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with estrogen and progestational agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 0
Study: 11024415

Group type: EXPERIMENTAL
Intervention: Early average intraocular pressure greater than 17.5 mm Hg
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: 100% of visits with intraocular pressure less than 18 mm Hg
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Less than 50% of visits with intraocular pressure less than 18 mm Hg
Number of subjects: 738
Study: 8640295

Group type: EXPERIMENTAL
Intervention: 300 micrograms potassium iodide/day
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no iodine supplementation)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups (iodine supplementation and control)
Number of subjects: 108
Study: 1478250

Group type: COMPARATOR
Intervention: BIM 23014 (1000, 2000, and 3000 micrograms as a 24 h s.c. infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: BIM 23014 (2000 micrograms daily for 7 days as a continuous s.c. infusion)
Number of subjects: 8
Study: 3884807

Group type: EXPERIMENTAL
Intervention: Prazosin (Minipress)
Number of subjects: 14
Study: 31422039

Group type: EXPERIMENTAL
Intervention: Experimental group received donkey milk, Badanmu, Chamagu compound containing a variety of protein nutritional preparations 20g/d.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group received basic treatment combined with nutrition treatment without additional protein preparations.
Number of subjects: 108
Study: 29422384

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine and amodiaquine plus a single dose of 0.25 mg/kg primaquine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus 15 mg/kg per day methylene blue for 3 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine and amodiaquine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 80
Study: 26352529

Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted distal gastrectomy (LADG)
Number of subjects: 1416
Study: 24655212

Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment (FBT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Separate group treatments of the overweight/obese parent and child (PC) - PC-1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Separate group treatments of the overweight/obese parent and child (PC) - PC-2
Number of subjects: 50
Study: 22496116

Group type: EXPERIMENTAL
Intervention: Decision aid (n=101)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care (n=103)
Number of subjects: 204
Study: 20546443

Group type: EXPERIMENTAL
Intervention: EGD-colonoscopy (Group I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Colonoscopy-EGD (Group II)
Number of subjects: 80
Study: 18573001

Group type: EXPERIMENTAL
Intervention: Source recall tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free recall tests
Number of subjects: 0
Study: 16642482

Group type: EXPERIMENTAL
Intervention: Self-reported goiter
Number of subjects: 29584
Study: 12942685

Group type: EXPERIMENTAL
Intervention: Optimal sampling design (D-optimal design)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Empirical sampling design
Number of subjects: 96
Study: 11340885

Group type: EXPERIMENTAL
Intervention: Optical pachometry
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasound pachometry
Number of subjects: 50
Study: 8977608

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intravenous doxapram
Number of subjects: 17
Study: 1731594

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (prednisolone) for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks
Number of subjects: 36
Study: 6609598

Group type: EXPERIMENTAL
Intervention: Golytely alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Golytely plus Dulcolax (bisacodyl)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard diet/cathartic preparation
Number of subjects: 200
Study: 30091172

Group type: EXPERIMENTAL
Intervention: Empa/Lina 10/5
Number of subjects: 223

Group type: COMPARATOR
Intervention: Empa/Plc 10/5
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Empa/Lina 25/5
Number of subjects: 223

Group type: COMPARATOR
Intervention: Empa/Plc 25/5
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Empa/Lina
Number of subjects: 223
Study: 28112426

Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg, three times daily for 2 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 25562853

Group type: EXPERIMENTAL
Intervention: Pedometer intervention encouraging 10,000 steps/day
Number of subjects: 0
Study: 23743811

Group type: EXPERIMENTAL
Intervention: Chronic resveratrol supplementation (75 mg daily for 6 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single dose of resveratrol (75 mg) after chronic supplementation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 21514710

Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no steroid)
Number of subjects: 33
Study: 18812241

Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Estrogen
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 16508131

Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment
Number of subjects: 0
Study: 14511272

Group type: EXPERIMENTAL
Intervention: Combined manipulative therapy and therapeutic exercise
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manipulative therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 200
Study: 11144946

Group type: EXPERIMENTAL
Intervention: Polyurethane stents (10 French diameter)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard plastic stents (10 French diameter)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both interventions (polyurethane and standard plastic stents)
Number of subjects: 38
Study: 8740309

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study: 1421932

Group type: EXPERIMENTAL
Intervention: traditional rice‐lentil (Khitchri) diet and yogurt (K‐Y)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: soy formula (alone for seven days and then in combination with K‐Y for seven days)
Number of subjects: 102
Study: 6420832

Group type: EXPERIMENTAL
Intervention: Chlorimipramine (CI) 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI) 25 mg
Number of subjects: 12
Study: 28224644

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection (ITDI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intratympanic normal saline injection (ITNI)
Number of subjects: 54
Study: 26626581

Group type: EXPERIMENTAL
Intervention: AZD4901 40 mg twice daily (BID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AZD4901 80 mg once daily (QD)
Number of subjects: 0
Study: 25652842

Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy
Number of subjects: 427

Group type: COMPARATOR
Intervention: Standard high-definition white light colonoscopy
Number of subjects: 427
Study: 23977910

Group type: EXPERIMENTAL
Intervention: 8 mg intravenous dexamethasone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 10
Study: 20360317

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10-40 mg/day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Lithium (300-1200 mg/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 18484901

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17029334

Group type: EXPERIMENTAL
Intervention: 40 mg of oral pravastatin once daily for up to 14 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12194927

Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.5 microg/kg of body weight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Omeprazole (20 mg twice a day for 4 days)
Number of subjects: 40
Study: 10604689

Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg twice daily for 1 month
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prosta-Q (quercetin, bromelain, and papain) in an open-label study
Number of subjects: 30
Study: 7577278

Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg (group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% Mepivacaine alone (group M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% Mepivacaine-Butorphanol (group MB)
Number of subjects: 0
Study: 1686130

Group type: EXPERIMENTAL
Intervention: Topical antipruritic corticosteroid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clemastine (sedative antihistamine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Terfenadine (non-sedative antihistamine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Number of subjects: 30
Study: 7198413

Group type: EXPERIMENTAL
Intervention: Halothane 3%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atropine 0.02 mg/kg followed by halothane 3%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Halothane 1.25% followed by succinylcholine 2 mg/kg
Number of subjects: 90
Study: 31985516

Group type: COMPARATOR
Intervention: Gemcitabine (6 cycles)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Erlotinib (100 mg/d)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Erlotinib
Number of subjects: 163
Study: 30409759

Group type: EXPERIMENTAL
Intervention: Quantitative Flow Ratio (QFR)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Functional SYNTAX score derived from QFR (fSSQFR)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Classic anatomic SYNTAX score
Number of subjects: 138
Study: 29166256

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26743136

Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg/die for 5 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Danazol 100 mg/die for 5 weeks
Number of subjects: 80
Study: 25246692

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (10 mg/kg per day for 15 days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg single dose)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg single dose) combined with Arachidonic acid (10 mg/kg per day for 15 days)
Number of subjects: 66
Study: 22759333

Group type: EXPERIMENTAL
Intervention: Lansoprazole with amoxicillin and clarithromycin (LAC)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Twice-daily dosage of PPI and clarithromycin
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Exact antibiotic dose per body weight
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Twice-daily PPI versus once daily for LAM regimen
Number of subjects: 222
Study: 19171708

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 189

Group type: COMPARATOR
Intervention: IFN-alpha-2a 9 million U three times weekly
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Sorafenib 600 mg twice daily (after progression)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily (after switch from IFN-alpha-2a)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 189

Group type: COMPARATOR
Intervention: IFN-alpha-2a
Number of subjects: 189
Study: 17593840

Group type: EXPERIMENTAL
Intervention: Eco-nutrition enteral nutrition (EEN)
Number of subjects: 32
Study: 15543326

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) treatment prior to elective surgery
Number of subjects: 71

Group type: COMPARATOR
Intervention: Untreated AAA patients (control group)
Number of subjects: 71
Study: 12393357

Group type: EXPERIMENTAL
Intervention: Remifentanil (continuous i.v. infusion starting at 0.025 micro g kg(‐1) min(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil (i.v. doses of 0.15 micro g kg(‐1))
Number of subjects: 60